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Background: We report herein a novel strategy for the preparation of protein-based nanode-
livery vehicles for hydrophobic active pharmaceutical ingredients.
Methods: The procedure consisted of three steps, ie, exposure of hydrophobic residues of 
a protein to a pH-induced partial unfolding: interaction between hydrophobic residues on 
the protein and the hydrophobic active pharmaceutical ingredient, and a final step where the 
structure of the protein was reversed to a native-like state by returning to neutral pH. As proof 
of concept, the interaction of paclitaxel with partially unfolded states of human serum albumin 
was evaluated as a potential method for the preparation of water-soluble complexes of the 
taxane with albumin.
Results: We found that paclitaxel readily binds to pH-induced partially unfolded albumin, leading 
to the formation of optically clear water-soluble complexes. The complexes thus formed were 
more stable in solution when the albumin native state was at least partially restored by neutral-
ization of the solution to a pH around 7. It was also observed that the hydrodynamic radius of 
human serum albumin was only slightly increased after the cycle of pH changes, remaining in 
a monomeric state with a size according to paclitaxel binding. Furthermore, paclitaxel binding 
did not affect the overall exposure of charged groups of human serum albumin, as evaluated by 
its interaction with an ionic exchange resin.
Conclusion: The in vitro biological activity of the complexes formed was qualitatively equiva-
lent to that of a Cremophor®-based formulation.
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Introduction
Paclitaxel (Taxol®, Bristrol-Myers Squibb, New York) is a very potent anticancer agent 
currently approved as first-line treatment for advanced carcinoma of the ovary, adjuvant 
treatment of breast carcinoma and nonsmall cell lung cancer, and as a second-line treat-
ment for Kaposi’s sarcoma related to acquired immunodeficiency syndrome.1,2 Because 
of its extremely poor aqueous solubility, paclitaxel has been formulated in ethanol and 
polyethoxylated castor oil (Cremophor EL®), a vehicle that has been associated with 
bronchospasm, hypotension, and various hypersensitivity reactions, in particular after 
rapid administration or 10 minutes after initiating drug infusion.3,4 Premedication with 
corticosteroids and antihistamines is mandatory to reduce the incidence of serious 
hypersensitivity   reactions. However, milder reactions still occur in 5%–30% of treated 
patients.5 To avoid the toxicities associated with the cosolvents required for taxane 
administration, and also to improve the solubility of paclitaxel, a number of alternative 
formulation strategies have been investigated.6–8 In this context, polyethylene glycol International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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was evaluated as a biocompatible polymer which improves 
water solubility of paclitaxel. However, the polyethylene 
glycol–paclitaxel   complex thus formed showed a decrease in 
antitumor   activity.3 Other polymers, such as hyaluronic acid, 
polyglutamic acid, and nucleic acids, have been evaluated 
as carriers to improve paclitaxel solubility. Although these 
complexes had a highly stable composition, the biological 
activity of the pharmaceutical principal was slow.9,10
Proteins have been used as carriers for hydrophobic 
drugs, especially human albumin.11–14 In this context, 
Desai et al described a composition for in vivo delivery of 
water-insoluble drugs, such as paclitaxel.11,15 In their report, 
paclitaxel was incorporated in a polymeric shell of albumin 
with a size no bigger than 10 µm, which was substantially 
crosslinked through disulfide bonds induced in the protein by 
sonication. Desai et al then described a new formulation to 
deliver paclitaxel.16 In this case, the agent was delivered in the 
form of suspended particles coated with a stabilizing protein. 
The complex of protein with drug is subjected to high shear, 
in the absence of conventional surfactants or any polymeric 
core, a procedure that yielded amorphous nanoparticles with 
a diameter of less than 200 nm. These results were the basis 
for the development of Abraxane®, a formulation approved 
by the US Food and Drug Administration for the treatment of 
metastatic breast cancer. However, the formulation developed 
has very limited stability upon reconstitution in saline solution 
(a maximum of 8 hours refrigerated at 2–8°C) and requires the 
use of a high-pressure homogenizer for its production.
The binding of paclitaxel to human serum albumin (HSA) 
has been studied using various methodologies.17–19 Most of 
these studies describe the interaction under physiological 
conditions and are primarily concerned with the determina-
tion of binding constants.20–22 Nevertheless, comparison of the 
reported data shows significant differences in affinity constant 
values, because the experimental conditions for carrying out 
binding experiments were indeed different.
Another important issue is that most of the formulations 
developed require the use of a percentage of organic solvent in 
order to deal with the very low solubility of paclitaxel in aque-
ous solution. The use of different organic solvents to prepare 
paclitaxel solutions indeed modifies the interaction process 
because the nature of paclitaxel binding to HSA is mainly 
hydrophobic. Because unfolding exposes the hydrophobic resi-
dues of proteins, we hypothesized that partially unfolded states 
of HSA could interact with paclitaxel,   leading to formation 
of water-soluble noncovalent complexes. The results reported 
here show that reversible acid-induced or alkali-induced 
denatured forms of albumin interact with paclitaxel, forming 
complexes that remain associated after protein renaturation, 
allowing paclitaxel delivery in   aqueous media.
Materials and methods
Paclitaxel was obtained from Yunnan Smandbet Co Ltd 
(Kunming, China). Stock solutions of paclitaxel were pre-
pared by dissolving the drug in either ethanol or dimethyl-
sulfoxide in a final concentration of 11.1 mg/mL. Further 
dilutions in organic solvent were prepared as necessary when 
assaying for different ratios and concentrations.
HSA 20% (w/v) with sodium caprylate (0.04 M) and 
N-acetyl tryptophan (0.04 M) as stabilizers was obtained 
from the Laboratorio de Hemoderivados, National University 
of Córdoba, Argentina. To remove the excipients, albumin 
was dialyzed against distilled water or saline solution, and 
diluted with distilled nonpyrogenic water to the final concen-
tration used in each assay. Defatted albumin was prepared 
by adsorption of fatty acids onto charcoal as previously 
described.23 Sodium dodecyl sulfate and urea were from 
Sigma Chemical Co (St Louis, MO). All other chemicals 
used were of analytical grade.
Turbidimetry
Optical density at a wavelength of 600 nm was used as a 
measure of the optical clarity of the samples.
Determination of hSA concentration
Protein concentration was determined using a Coomassie 
Brilliant blue assay or by direct absorbance at 280 nm, as 
previously described.24
Determination of paclitaxel 
concentration
Paclitaxel concentration was measured on a Curosil B C18 
column (250 × 3.20 mm ID, particle size 5 µm) and a Curosil 
B C18 guard column (30 × 4.60 mm ID, particle size 5 µm) 
supplied by Phenomenex (Torrance, CA). The mobile phase 
was 60% (v/v) acetonitrile and 40% (v/v) biodistilled water. 
Flow rate was 0.7 mL/min and the eluent was monitored at 
227 nm. Chromatography was performed at ambient tem-
perature (20 ± 2°C).
Protein chromatography
Reaction mixtures and controls were chromatographed on an 
Äkta Explorer 100 system (GE Healthcare, Barrington, IL) 
fitted with a Superdex 200 or Mono Q column   previously 
equilibrated with 50 mM phosphate buffer (pH 7.0) and 
100 mM NaCl (phosphate-buffered saline). The elution International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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profile was followed using an ultraviolet detector at 280 nm, 
and the total protein levels were quantified using a Coomassie 
brilliant blue assay.24 Molecular weight markers in concentra-
tions of 3 mg/mL were run similarly, and fractions analyzed 
for protein content using the Coomassie brilliant blue assay. 
HSA was eluted from the anion exchange resin with 50 mM 
sodium phosphate pH 7.0, 0.5 M NaCl.
Water-soluble paclitaxel noncovalently 
bound to albumin
Paclitaxel was solubilized in an organic solvent, such as ethanol 
or dimethylsulfoxide, and the solutions were then centrifuged 
to remove any potential particles. The solutions were slowly 
added under gentle agitation to the solution of HSA previ-
ously adjusted to the different conditions to be tested. After 
1 hour of stabilization at the selected experimental conditions 
(temperature, pH, and ionic strength), the pH was slowly 
adjusted to 7.0 ± 0.2 with 1 M Tris-HCl pH 7.0, if necessary, 
and the paclitaxel precipitated was removed by centrifugation 
(14,000 × g, 10 minutes) at a series of time intervals. Finally, an 
aliquot of supernatant (300 µL) was filtered through 0.2 µm and 
the concentration of paclitaxel in solution (bound and unbound 
to HSA) was determined by reverse-phase high-pressure liquid 
chromatography. The amount of insoluble paclitaxel was deter-
mined from the precipitates by reverse-phase high-pressure 
liquid chromatography after its solubilization in ethanol.
human larynx epithelioma cell culture 
conditions
Human larynx epithelioma cells (ATCC CCL-23) were 
propagated in minimum essential medium supplemented with 
10% irradiated fetal bovine serum (Natocor, Córdoba, Argen-
tina), 100,000 IU/L penicillin (Life Technologies, Rockville, 
MD), and 2 mM L-glutamine (Sigma). Cell monolayers were 
incubated in the above medium in the presence or absence 
of different concentrations of paclitaxel: HSA or paclitaxel 
in Cremophor (control) over 24 hours. Cell viability was 
assayed by trypan blue exclusion. Cell monolayers were 
photographed without any staining in an Axiovert 135 M 
Carl-Zeiss microscope at 50 × (Oberkochen, Germany).
Results and discussion
Solubilization of paclitaxel by interaction 
with reversibly denatured hSA
It is known that HSA undergoes reversible conformational 
isomerization with changes in pH of the solution containing 
the protein.25,26 At neutral pH, HSA assumes the normal form, 
which abruptly changes to a highly charged fast migrating 
form at pH values lower than 4.3 because this form moves 
“fast” on gel electrophoresis. In this condition, albumin is 
in a compact partially denaturated state, with a significant 
amount of secondary structure but a largely disordered tertiary 
structure.27 Upon further reduction in pH to lower than 2.7, 
the protein structure changes to the fully extended form. The 
α-helix content decreases to a minimal value of 25%, and 
HSA is in an expanded form and increases the exposure of 
its hydrophobic surface.25,26 On the other hand, an increase in 
pH to 10 also induces a reversible denaturation of HSA that 
exposes part of its hydrophobic residues.28,29 We hypothesized 
that these reversible partially denaturated structures could 
contribute to the binding of a highly hydrophobic molecule 
such as paclitaxel, leading to the formation of soluble com-
plexes. As shown in Table 1, not only does paclitaxel form 
clearer solutions when incubated with denatured acid than 
with native HSA, but also a proportion of the complexes thus 
formed remains soluble even after pH is reversed to 7. The 
differences between the preparations are also reflected in the 
dramatic differences in their turbidity which, when measured 
before clarification by centrifugation, turned out to be a good 
predictor of the outcome in terms of paclitaxel solubilization 
Table 1 effect of ph on the turbidity and solubility of Ptx–hSA complexes
Ptx: HSA 
Molar 
ratio
Sample incubated at pH 2.7  
(1 h) adjusted pH to 7.0
Sample incubated at  
pH 7.0 (1 h)
Sample incubated at pH 10.0  
(1 h) adjusted pH to 7.0
Pre-centrif. OD  
(600 nm)
Soluble 
Ptx 
(μg ⋅ mL-1)
Pre-centrif. OD  
(600 nm)
Soluble 
Ptx 
(μg ⋅ mL-1)
Pre-centrif. OD 
(600 nm)
Soluble 
Ptx 
(μg ⋅ mL -1)
9:1 0.543 355 1.824 BDL 0.503 406
4:1 0.596 446 1.483 BDL 0.604 442
2:1 0.664 455 1.386 BDL 0.694 434
Note: *Samples of hSA were adjusted to ph 2.7, 7.0 or 10.0 and kept at 25°C during 1 hour, afterwards, 0.1 volume of Ptx in ethanol was added to reach a final Ptx 
concentration of 1 mg ⋅ mL-1 ⋅ The samples were incubated at 25°C during 1 hour and then the ph was adjusted to 7.0 with 0.1 N NaOh or hCl. Finally all samples were 
clarified by centrifugation at 14,000 × g during 10 minutes and the concentration of soluble Ptx was determined by RP-hPLC as described under materials and methods. In all 
cases OD at 600 nm after centrifugation was below 0.1. Results are the means of three different experiments performed in duplicates. RSD were all 10%.
Abbreviations: BDL, below detection limit; Ptx, Paclitaxel; OD, optical density; RSD, relative standard deviation.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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(Table 1). It is important to stress the fact that all samples were 
optically clear (OD at 600 nm  0.1) after centrifugation. 
Similar results were obtained when defatted or excipient-free 
HSA was used, suggesting that neither fatty acids nor sodium 
caprylate or N-acetyl tryptophan interfere with binding of 
paclitaxel to HSA (data not shown). Incubation at an alkaline 
pH also rendered optically clear solutions of paclitaxel and 
HSA (Table 1).
effect of incubation temperature on binding 
paclitaxel to hSA
In an attempt to optimize the binding of paclitaxel to partially 
unfolded albumin, we evaluated the effect of incubation tem-
perature on the formation of water-soluble paclitaxel–HSA 
complexes with different molar ratios exposing hydrophobic 
surfaces of HSA by acid pH. As expected, a lowered incuba-
tion temperature rendered the system more hydrophobic, and 
led to clearer solutions and an increased amount of paclitaxel 
remaining solution (Table 2).
It was also observed that the mixtures prepared at a low 
incubation temperature remained clearer and more soluble 
for at least a week at 4°C, indicating that the complexes 
formed had greater stability (data not shown). Upon 
increasing the temperature from 4°C to 37°C, unacceptable 
formulation mixtures were obtained due to increased precipi-
tation of paclitaxel and HSA. Similar results were obtained 
at alkaline pH, except that at a pH of 10, the ester bond in 
paclitaxel was rapidly hydrolyzed at high temperatures (data 
not shown).
effect of ionic strength on formation of water-
soluble paclitaxel–hSA complexes
Given the zwitterionic character of HSA and the hydropho-
bicity of paclitaxel, the ionic strength of the aqueous media 
is almost certainly a variable that will affect the formation 
of water-soluble complexes between paclitaxel and HSA. 
First, an increase in ionic strength could reinforce and sta-
bilize the mainly hydrophobic interaction of paclitaxel with 
HSA. On the other hand, using a high protein concentration, 
increasing ionic strength could promote interaction among 
albumin molecules, leading to a decrease in stability with a 
concomitant increase in turbidity of the solution. Although 
not statistically significant, a slight improvement in pacli-
taxel solubility was apparent with the addition of NaCl up 
to 0.4 M, suggesting that the addition of salt reinforces and 
stabilizes the   interaction of paclitaxel with HSA (Table 3). 
Table 2 effect of incubation temperature on the turbidity and solubility of Ptx–hSA complexes
Ptx:HSA 
Molar 
ratio
Incubation temperature
4°C 25°C   37°C
Pre-centrif. OD 
(600 nm)
Soluble Ptx 
(μg ⋅ mL-1)
Pre-centrif. OD 
(600 nm)
Soluble Ptx 
(μg ⋅ mL-1)
Pre-centrif. OD 
(600 nm)
Soluble Ptx   
(μg ⋅ mL-1)
9:1 0.123 328 0.352 240 1.041 76
4:1 0.154 257 0.386 213 0.694 36
2:1 0.203 252 0.686 179 0.760 BDL
Note: Samples of hSA were adjusted to ph 2.7 and kept at 4, 25 or 37°C during 1 hour, afterwards, 0.1 volume of Ptx in ethanol was added to reach a final Ptx concentration 
of 0.5 mg ⋅ mL-1. The samples were incubated at 4, 25 or 37°C during 1 hour and then the pH was adjusted to 7.0 with 0.1 N NaOH. Finally, all samples were clarified by 
centrifugation at 14,000 × g during 10 minutes and the concentration of soluble Ptx was determined by RP-hPLC as described under materials and methods. Results are the 
means of three different experiments performed in duplicates. RSD were all 10%.
Abbreviations: Ptx, Paclitaxel; OD, ; RSD, .
Table 3 effect of ionic strength on the optical clarity and solubility of Ptx–hSA complexes
NaCl (M) Sample incubated at pH2.7* Sample incubated at pH 2.7 (1 h) adjusted pH to 7.0**
Pre-centrif. OD 
(600 nm)
Soluble Ptx 
(μg ⋅ mL-1)
Bound  
Ptx (%)
Pre-centrif. OD 
(600 nm)
Soluble Ptx 
(μg ⋅ mL-1)
Bound  
Ptx (%)
0 0.266 BDL BDL 0.375 815 81.5
0.2 0.196 869 86.9 0.295 832 83.2
0.4 0.196 890 89.0 0.298 910 91.0
0.6 0.223 891 89.1 0.310 880 88.0
0.8 0.425 465 46.5 0.460 795 79.5
1:0 .2 BDL BDL .2 BDL BDL
(Precipitated) (Precipitated)
Note: *Samples of hSA (20 mg ⋅ mL-1) were adjusted to ph 2.7 and kept at 4°C during 1 hour, afterwards, 0.1 volume of Ptx in ethanol was added to reach a final Ptx 
concentration of 1 mg ⋅ mL-1 ⋅ The samples were incubated at 4°C during 1 hour and then samples labeled **were adjusted to ph 7.0 with 0.1 N NaOh. All samples were 
incubated 1 h at 4°C, clarified by centrifugation at 14,000 × g during 10 minutes and the concentration of soluble Ptx was determined by RP-hPLC as described under 
materials and methods. Results are the means of three different experiments performed in duplicates. RSD were all 10%.
Abbreviations: BDL, below detection limit; RSD, relative standard deviation; Ptx, Paclitaxel; OD, optical density.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 Size exclusion chromatography of hSA and paclitaxel–hSA. Chromatography on Superdex 200® of hSA (-----) and hSA-paclitaxel. Samples of hSA 5 mg (10 mg/mL) 
and hSA-paclitaxel 2 mg (10 mg/mL hSA and 1.11 mg/mL paclitaxel) were run on a Superdex 200® column (hR 10/30) at room temperature in phosphate-buffered saline as 
described in the Materials and methods section. 
Abbreviations: hSA, human serum albumin; Ptx, Paclitaxel.
Table 4 Binding of Ptx–hSA to anion exchange resin
Paclitaxel: 
HSA Molar  
ratio
Nonbound to Mono Q Eluted from Mono Q
HSA (%) Paclitaxel (%) HSA (%) Paclitaxel (%)
9:1 5.0 22 95 80
4:1 8.0 14 92 82
2:1 7.0 16 93 85
Note: Results are the means of three different experiments performed in duplicate. 
RSD were all 10%.
Abbreviations: RSD, relative standard deviation; Ptx, Paclitaxel.
As expected, we found that a gel was formed at a high ionic 
strength and an acidic pH, and this led to marked precipita-
tion of protein and turbid mixtures (Table 3). This effect 
was even more sensitive to salt concentration when the HSA 
concentration was 40 mg/mL, at which a gel was formed 
with 0.6 M NaCl, whereas at 60 mg/mL a gel was formed 
with 0.4 M NaCl.
Chromatography of paclitaxel–hSA complexes
To explore the structural properties of the complexes formed 
between paclitaxel and acid-denatured HSA, samples of the 
soluble complexes formed were run on size exclusion and 
ionic exchange chromatography columns. As determined by 
reverse-phase high-pressure liquid chromatography analysis 
of the fractions, paclitaxel coeluted with HSA from a size 
exclusion resin indicating that there is a physical association 
between them (data not shown). It was also observed that 
the elution volume of HSA changed slightly upon binding 
of paclitaxel, suggesting that it remains monomeric and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1198
Garro et al
0
20
40
60
80
100
120
140
0123456789 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Elution volume (mL)
A
b
s
,
 
2
8
0
 
n
m
 
(
m
A
U
)
0
200
400
600
800
1000
1200
N
a
C
l
 
(
m
M
)
0
200
400
600
800
1000
1200
1400
1600
0123456789 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Elution volume (mL)
A
b
s
,
 
 
2
2
7
 
n
m
 
(
m
A
U
)
0
200
400
600
800
1000
1200
N
a
C
l
 
(
m
M
)
 
------ HSA    Ptx–HSA
------ HSA    Ptx–HSA
Figure 2 Ionic exchange chromatography of hSA and paclitaxel–hSA complexes. Chromatography on Mono Q® of hSA (-----) and hSA-paclitaxel. Samples of 0.5 mg hSA 
(1 mg/mL) and 1.25 mg hSA-paclitaxel (5 mg/mL hSA and 0.214 mg/mL paclitaxel) were bound to a Mono Q® column (hR 5/5) at room temperature in 50 mM sodium 
phosphate (ph 7.0) and eluted with 0.3 M NaCl in 50 mM sodium phosphate (ph 7.0). 
Abbreviation: hSA, human serum albumin.
globular, with a hydrodynamic radius in agreement with 
that expected for HSA complexed with 4–6 molecules of 
paclitaxel (Figure 1). In agreement with this finding, more 
than 90% of the albumin and paclitaxel were bound and 
coeluted from an ionic exchange resin, with a profile simi-
lar to that of pure HSA (Table 4 and Figure 2). Altogether, 
these results confirm that paclitaxel is solubilized in water 
through a physical interaction with HSA, and also provide 
evidence suggesting that the complexes formed do not 
substantially modify the hydrodynamic radius or the net 
charge of HSA.
evaluation of biological activity of water-soluble 
paclitaxel–hSA complexes
The test used to evaluate the biological activity of the 
paclitaxel–albumin complex was the inhibition of division 
of a tumoral cell line. As seen in Figure 3, control samples 
show a clear monolayer of human larynx epithelioma cells 
covering the surface of the Petri dishes. On the other hand, 
cell samples treated with paclitaxel either in Cremophor or 
complexed with HSA show few cells, indicating that albumin 
does not impair the biological effect of paclitaxel on cell 
division. Furthermore, at least at the dose tested, there was International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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A
B
C
Figure 3 effect of paclitaxel in hSA or Cremophor® on hep-2 cells. Monolayers 
of  hep-2  cells  without  paclitaxel  A),  with  10  µg/mL  paclitaxel  solubilized  in 
Cremophor® B) or complexed with hSA C). 
Abbreviations: hep-2, human larynx epithelioma; hSA, human serum albumin.
no statistical difference in the number of viable cells between 
paclitaxel in Cremophor and those complexed with HSA.
Conclusion
Standard formulations of  taxanes require use of solvents, such   
as Cremophor or Tween, which contribute to some of the tox-
icities associated with paclitaxel-based therapy. To overcome 
these drawbacks, nanoparticle HSA-bound paclitaxel has 
been recently approved and is available commercially as 
Abraxane®. However, this formulation is prepared by high-
pressure homogenization of albumin and paclitaxel, leading 
to the formation of a colloidal suspension with very limited 
stability. We hypothesized that the exposure of hydrophobic 
domains of albumin via a partial opening of its structure could 
improve its interaction with a hydrophobic molecule like 
paclitaxel. The results obtained confirm that, as previously 
known, the binding affinity of paclitaxel with native HSA is 
very low (Table 1).15 In agreement with our hypothesis, we 
found that paclitaxel readily binds to pH-induced partially 
unfolded HSA, leading to the formation of optically clear 
water-soluble complexes. The complexes thus formed appear 
to be more stable in solution when the native state of HSA is 
at least partially restored by neutralization of the solution to 
a pH around 7. In agreement with this, we observed that the 
hydrodynamic radius of HSA is only slightly affected after 
the cycle of pH changes, and is consistent with paclitaxel 
binding. Furthermore, paclitaxel binding does not affect the 
overall exposure of charged groups of HSA, as evaluated 
by its interaction with an ionic exchange resin. The in vitro 
biological activity of the complexes formed was qualitatively 
equivalent to that of a Cremophor-based formulation.
In conclusion, our results not only show that HSA-paclitaxel 
complexes can be prepared by a simple method that does not 
require use of high-pressure homogenization, but also open up 
the possibility to extend this strategy for the design of novel 
protein-based nanodelivery vehicles for other hydrophobic active 
pharmaceutical ingredients. Further work is in progress in order 
to characterize the structure, as well as energetic and dynamic 
parameters of the complexes formed by the binding of pacli-
taxel to partially unfolded HSA and to evaluate their activity.
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